Antibodies News and Research

RSS

Horizon Discovery licenses CHOSOURCE to Sanyou Biopharmaceuticals Co.

Horizon Discovery today announced that it has granted commercial licenses for its cGMP-compliant CHOSOURCE™ platform to Sanyou Biopharmaceuticals.

From Revvity 2 Dec 2020

Researchers evaluate the most appropriate test for COVID-19

Until a vaccine is available, curbing the coronavirus pandemic relies heavily on how quickly a potentially exposed individual can be tested and quarantined.

2 Dec 2020

Researchers study SerpinB9 protein that could pave way to new immunotherapy approach

Immunotherapies have transformed the landscape of cancer treatment by allowing physicians to alter or augment patients' immune response to better attack malignant tumors.

2 Dec 2020

Nanomedicine's giant step into the fight against the COVID-19

A recent editorial in Nature Nanotechnology discusses the enormous feat of scientific innovation, with messenger RNA (mRNA)-based vaccines developed to deliver the gene sequence of specific SARS-CoV-2 viral proteins into host cells using nanotechnology platforms.

1 Dec 2020

KU Leuven vaccine candidate works against yellow fever and SARS-CoV-2 infection

Virologists at the Rega Institute at KU Leuven (Belgium) have developed a vaccine candidate against Covid-19 based on the yellow fever vaccine, which as a result also works against yellow fever. Results published today in Nature show that the vaccine protects hamsters from infection with the SARS-CoV-2 coronavirus after a single dose.

1 Dec 2020

How COVID-19 highlights the uncertainty of medical testing

Dr. Jacqueline Chu considered the man with a negative coronavirus test on the other end of the phone, and knew, her heart dropping, that the test result was not enough to clear him for work.

1 Dec 2020

Chinese woman still sheds SARS-CoV-2 over four months post-infection

A new study by Chinese scientists explore an unusual case of extended viral shedding in a 68-year-old woman up to four months post-infection.

1 Dec 2020

Low endorsement among doctors worldwide for COVID-19 ‘immunity passports’

A cross-sectional survey conducted in September 2020, aimed at assessing the views of a randomly selected, stratified physician sample on this matter, drawing names from physicians registered with the global networking platform called Sermo. This offers its registration service to verified licensed physicians.

1 Dec 2020

Researchers report AI solution that could revolutionize medical research

Inside every cell, thousands of different proteins from the machinery that keeps all living things - from humans and plants to microscopic bacteria - alive and well. Almost all diseases, including cancer, dementia, and even infectious diseases such as COVID-19, are related to the way these proteins function.

1 Dec 2020

Nucleic acid-hydrolyzing scFv 3D8 exhibits potent antiviral effects on SARS-CoV-2

3D8, a 27-kDa recombinant antibody fragment, was found in autoimmune-prone Murphy Roths Large mice. The single-chain variable fragment (scFv) has the nucleic acid hydrolyzing activity and is shown to degrade DNA or mRNA of viruses in infected cells.

30 Nov 2020

Good cholesterol helps SARS-CoV-2 enter cells

The researchers explained that the SARS-CoV-2 can infect human host cells after its viral spike protein (SARS-2-S) binds to a cellular surface receptor called the angiotensin-converting enzyme 2 (ACE2).

30 Nov 2020

Infection control, widespread testing help reduce SARS-CoV-2 transmission in schools, study finds

Now, a team of researchers at the New York University Grossman School of Medicine explored which school policies had the most significant impact on reducing the risk of in-school SARS-CoV-2 transmission.

30 Nov 2020

Memory B cells persist in recovered COVID-19 patients

A team of scientists from the University of Washington, USA, and the Karolinska Institute, Sweden, has comprehensively studied the antibody-mediated immune responses in patients diagnosed with coronavirus disease 2019 (COVID-19).

30 Nov 2020

Wyss Institute’s eRapid technology licensed to The iQ Group Global

Today, the Wyss Institute for Biologically Inspired Engineering at Harvard University announced that its eRapid technology has been licensed to The iQ Group Global for COVID-19 diagnostic applications.

30 Nov 2020

SARS-CoV-2 immunity in the U.S. remains low

Seroprevalence studies indicate that less than 10% of people in the U. S. have detectable antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from July to September 2020.

30 Nov 2020

Experimental vaccine protects cynomolgus macaques against Crimean-Congo hemorrhagic fever virus

An experimental vaccine developed in Europe to prevent infection by Crimean-Congo hemorrhagic fever virus (CCHFV) has protected cynomolgus macaques in a new collaborative study from National Institutes of Health scientists.

30 Nov 2020

A mutant SARS-CoV-2 subspecies from minks may evade antibody detection

In a recent research letter published on the bioRxiv preprint server, scientists from Japan discovered that the mutation of spike glycoprotein in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) derived from farmed minks can also be found in the group of individuals with coronavirus disease (COVID-19) and subsequently evade detection by our immune system.

30 Nov 2020

Highly functional immune response in asymptomatic SARS-CoV-2 infection

Researchers in Singapore have conducted a study showing that asymptomatic individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – mount an efficient, balanced and coordinated cellular immune response that protects the host without appearing to trigger any pathological processes.

30 Nov 2020

Combination therapy found to be effective against treatment-resistant hepatocellular carcinoma

A combination cancer therapy that is effective against treatment-resistant hepatocellular carcinoma (HCC) by inhibiting tumor growth and increasing survival has been identified by researchers at Massachusetts General Hospital.

30 Nov 2020

Severe COVID-19 can produce high long-term neutralizing antibodies, study finds

A new study published by a team of scientists in Spain indicates that neutralizing immunity can last for up to 8 months, despite a steep drop in antibody titer over this time.

30 Nov 2020